New insights into neuromyelitis optica.

Area of Science:

• Neuroimmunology
• Central Nervous System Disorders
• Autoimmune Diseases

Background:

• Neuromyelitis optica (NMO) was historically considered a subtype of multiple sclerosis (MS), particularly in Asia.
• Recent research highlights distinct clinical, pathological, immunological, and imaging features differentiating NMO from MS.
• The discovery of NMO-IgG, an autoantibody targeting aquaporin-4 (AQP4), revolutionized NMO understanding.

Purpose of the Study:

• To review the evolving concepts of Neuromyelitis Optica (NMO) based on its pathophysiology and clinical presentation.
• To discuss the significance of anti-aquaporin-4 (AQP4) antibodies in NMO diagnosis and prognosis.
• To explore potential management strategies informed by NMO's pathomechanisms.

Main Methods:

• Literature review focusing on clinical, pathological, immunological, and imaging studies.
• Analysis of diagnostic criteria evolution incorporating NMO-IgG (anti-AQP4 antibody) findings.
• Synthesis of current understanding regarding NMO spectrum disorders and their pathogenesis.

Main Results:

• NMO is now recognized as distinct from MS, with anti-AQP4 antibody demonstrating high specificity for diagnosis.
• The spectrum of NMO is broader, including NMO spectrum disorders (NMOSD) with various clinical presentations.
• Seropositivity for NMO-IgG is a validated prognostic marker for NMOSD relapses.

Conclusions:

• Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSD) are distinct CNS inflammatory conditions.
• Anti-aquaporin-4 (AQP4) antibody testing is crucial for accurate NMO diagnosis and understanding disease mechanisms.
• Further research is needed to elucidate the role of NMO-IgG in animal models and develop targeted therapies.